Video

Diabetes Meds

Davida Kruger discusses SGLT2 medications—a new class of diabetes drugs—and its mechanism of action and the benefits. Interviewed by Mimi Secor, MS, MEd, APRN, BC, FNP, FAANP

Publish date: December 12, 2013
Author(s):
Davida Kruger, MSN, APRN-Bc, BC-ADM
Author and Disclosure Information

 

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

To hear her lecture on “Cost-Effective Diabetes Treatment for the Under-Uninsured,” and earn CE/CME credit, please attend the 2013 MEDS West in Irvine, CA, October 3-5. Click here for complete details.

Recommended Reading

Hereditary Hemochromatosis as a Cause of Hypogonadism
Clinician Reviews
Unsuspected Primary Hyperparathyroidism Common in Fibromyalgia Patients
Clinician Reviews
World’s Dialysis Burden Has Grown 165%
Clinician Reviews
Testosterone for ‘low T’ Raises Death, MI, and Stroke Risk
Clinician Reviews
FDA Moves to Reduce or Remove Trans Fats from Foods
Clinician Reviews
Knee Osteoarthritis Often Overlooked in the Obese
Clinician Reviews
Soda Boosts Rheumatoid Arthritis Risk
Clinician Reviews
Combined Angiotensin Inhibition Raises Hyperkalemia, Acute Kidney Injury Risks
Clinician Reviews
FDA Lifts Rosiglitazone Prescribing Restrictions
Clinician Reviews
Vegetarian, Vegan Diets for Weight Loss?
Clinician Reviews